Co- and Posttranslational Translocation Mechanisms Direct Cystic Fibrosis Transmembrane Conductance Regulator N Terminus Transmembrane Assembly*

Yun LuDagger , Ximing XiongDagger , Andrew Helm, Kabuiya Kimani, Alvina Bragin, and William R. Skach§

From the Department of Molecular and Cellular Engineering and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Transmembrane topology of most eukaryotic polytopic proteins is established cotranslationally at the endoplasmic reticulum membrane through the action of alternating signal and stop transfer sequences. Here we demonstrate that the cystic fibrosis transmembrane conductance regulator (CFTR) achieves its N terminus topology through a variation of this mechanism that involves both co- and posttranslational translocation events. Using a series of defined chimeric and truncated proteins expressed in a reticulocyte lysate system, we have identified two topogenic determinants encoded within the first (TM1) and second (TM2) membrane-spanning segments of CFTR. Each sequence independently (i) directed endoplasmic reticulum targeting, (ii) translocated appropriate flanking residues, and (iii) achieved its proper membrane-spanning orientation. Signal sequence activity of TM1, however, was inefficient due to the presence of two charged residues, Glu92 and Lys95, located within its hydrophobic core. As a result, TM1 was able to direct correct topology for less than half of nascent CFTR chains. In contrast to TM1, TM2 signal sequence activity was both efficient and specific. Even in the absence of a functional TM1 signal sequence, TM2 was able to direct CFTR N terminus topology through a ribosome-dependent posttranslational mechanism. Mutating charged residues Glu92 and Lys95 to alanine improved TM1 signal sequence activity as well as the ability of TM1 to independently direct CFTR N terminus topology. Thus, a single functional signal sequence in either the first or second TM segment was sufficient for directing proper CFTR topology. These results identify two distinct and redundant translocation pathways for CFTR N terminus transmembrane assembly and support a model in which TM2 functions to ensure correct topology of CFTR chains that fail to translocate via TM1. This novel arrangement of topogenic information provides an alternative to conventional cotranslational pathways of polytopic protein biogenesis.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Eukaryotic polytopic integral membrane proteins acquire proper transmembrane orientation through the action of discrete topogenic determinants (i.e. signal, stop transfer, and signal anchor sequences) encoded within transmembrane segments and their flanking residues (1-3). It has been proposed that, like secretory (4) and bitopic transmembrane proteins (5, 6), polytopic topology is established cotranslationally as these topogenic determinants emerge from ER1-bound ribosomes and direct sequential rounds of translocation initiation, termination, and membrane integration (1, 7-9). Consistent with this view, any given polytopic orientation may be generated de novo from combinations of signal, stop transfer, and/or signal anchor sequences engineered into a single polypeptide (10-12). Similarly, independent topogenic determinants have been identified from eukaryotic proteins such as bovine rhodopsin (13, 14), acetylcholine receptor (15, 16), P-glycoproteins (17-19), aquaporins (20, 21), band 3 anion exchanger (22), and calcium and P-type ATPases (23, 24). Whereas the molecular details of polytopic protein assembly into the ER membrane remain largely unknown, this process appears to require cytosolic and membrane bound components of the ER translocation machinery including signal recognition particle (25), the Sec61 complex, and TRAM (18, 26, 27).

If polytopic proteins followed a strict mechanism of cotranslational translocation, then failure of a given topogenic determinant to target or translocate the nascent chain at the ER membrane would result in irreversible protein misfolding. Structural requirements for directing protein topology would therefore be predicted to significantly restrict sequence diversity of topogenic determinants (e.g. transmembrane (TM) segments and/or their flanking regions). For this reason, certain polytopic proteins appear to have developed variations on cotranslational assembly pathways. For example, during transmembrane assembly of the Escherichia coli lac permease protein, interactions between TM9 and TM10 were required to correctly position residue Arg302 within the bilayer and to ensure transmembrane topology of the TM9-10 peptide loop (28, 29). Similarly, membrane integration of human P-glycoprotein (MDR1) into the lipid bilayer required cooperativity between independent signal sequences encoded within TM1 and TM2 (18). More recently, it was shown that interactions between topogenic determinants within the yeast protein Sec61p were involved in directing topology of weakly hydrophobic internal transmembrane segments (30). Finally, it has been shown in vitro that some but not all polytopic proteins are capable of assembling posttranslationally into the ER membrane after polypeptide synthesis has been completed (8, 31, 32). Despite these studies however, the mechanisms by which multiple topogenic determinants cooperate to direct complex topology in a non-cotranslational manner remain poorly understood.

In the current study we examine the biogenesis of the cystic fibrosis transmembrane conductance regulator, CFTR, and show that both cotranslational and posttranslational mechanisms are involved in establishing correct topology of the first two N terminus transmembrane segments. This mechanism of assembly resulted from the presence of charged residues (Glu92 and Lys95) located within the hydrophobic core of TM1, which markedly decreased TM1 signal sequence activity. Thus TM1 was capable of directing translocation for only a subset of CFTR chains, whereas signal sequence activity of TM2 was required to direct topology of remaining chains. CFTR N terminus biogenesis therefore does not rely on the sequential action of independent topogenic sequences to establish its multispanning topology. Rather CFTR utilizes two distinct and redundant translocation pathways: a cotranslational pathway directed by TM1 and a ribosome-dependent posttranslational pathway directed by TM2. An important consequence of this mechanism is that redundant topogenic information encoded by TM2 enables TM1 to acquire critical structural features that would otherwise interfere with conventional cotranslational assembly.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

cDNA Construction-- E92A and K95A mutations were engineered into CFTR by site-directed mutagenesis using a single stranded (M-13) (plasmid pBQ 4.7) template and oligonucleotides TATATTTAGGCGCCGTCACCAAAGCAGT and GAAGTCACCGCTGCAGTACAGCCT as described (33). AvaI/XbaI fragments containing the engineered mutations were then ligated into an AvaI/XbaI-digested pSPCFTR vector (34), generating plasmids pSPCFTR(E92A) and pSPCFTR(K95A). Plasmid pSPCFTR(E92A/K95A) was generated by PCR amplification of pSPCFTR(E92A) (sense primer (SP6 promoter) ATTTAGGTGACACTATAG, and antisense primer TACTGCAGCGGTGACGGCGCCTAA), digestion of the PCR fragment with AvaI/PstI (PstI encoded in antisense oligonucleotides) and ligation of the fragment into an AvaI/PstI digested pSPCFTRK95A vector. Plasmids pSPCFTR(G85E) and pSPCFTR(G91R) are described elsewhere (33). Plasmids TM1.P, TM1.P(G85E), TM1.P(G91R), TM1.P(E92A), TM1.P(E95A), and TM1.P(E92A/E95A) were constructed by PCR amplification of WT or corresponding mutant CFTR plasmids (sense primer (SP6 promoter), antisense primer TAGATAGGTCACCATAGAGCGTTCCTCCT) and ligation of HindIII/BstEII-digested PCR fragments into a HindIII/BstEII-digested vector, S.L.ST.gG.P (described in Ref. 18). The resulting plasmids encode the CFTR N terminus through residue Ser118 fused to a 142 residue C terminus fragment (P) of bovine prolactin (11).

CFTR mutations Delta E115, E116K, E115K/E116K, and G126D were engineered by PCR overlap extension (35) using sense primers: 1) CCGGATAACAAGGAACGCTCTATC, 2) GATAACAAGGAGAAACGCTCTATCGCG, 3) AACAAGAAAAAACGGTCCATCGCGATTTATCTAGGC, 4) GATTTATCTAGGCATAGACTTATGCCTTCTC, respectively, and complimentary antisense primers (not shown) to generate overlapping 5' and 3' PCR fragments. These fragments were fused in a subsequent PCR reaction as described (35). PCR fragments from this "fusion" reaction were digested with AvaI/XbaI and ligated into AvaI/XbaI-digested pSPCFTR vector. Plasmids TM1-2.P encoding Delta E115, E116K, E115K/E116K, and G126D mutations were generated by PCR amplification of respective mutant pSPCFTR plasmids using sense primer (SP6 promoter) and antisense primer 5) AAATTTGGTCACCTTGTTGGAAAGGAGACT. PCR fragments were digested with HindIII/BstEII and ligated into a HindIII/BstEII-digested vector S.L.ST.gG.P (18). Resultant plasmids encode CFTR residues Met1-Asn186 followed by the P reporter. Plasmids TM1-2.P encoding mutations E116K/G126D and E115K/E116K/G126D were constructed by PCR overlap extension using primers 2 and 3 and pSPCFTR(G126D) template. Similarly, plasmids TM1-2.P containing E92A/K95A mutations together with (a) E115K/E116K, (b) E116K/G126D, or (c) E115K/E116K/G126D were generated by PCR overlap extension using the following strategies: (a) primer 3 (pSPCFTR(E92A/K95A) template); (b) primer 2 and (5' template pSPCFTR(E92A/K95A) and 3' template pSPCFTR(G126D); (c) primer 3 (5' template pSPCFTR(E92A/K95A) 3' template pSPCFTR(G126D)). Fusion PCR products from these reactions were digested with HindIII/BstEII and ligated into HindIII/BstEII-digested S.L.ST.gG.P. Plasmids encoding G85E together with E115K/E116K, E116K/G126D or E115K/E116K/G126D mutations were made in the identical manner except that pSPCFTR(G85E) was used as the template for the initial 5' PCR reactions. ggTM2.P plasmids were generated by PCR amplification of WT and mutant CFTR using sense primer TACTGGCCATGGTCAACGCTTCCTATGACCCG and antisense primer 5. Resulting fragments were digested with NcoI (encoded in sense primer) and BstEII and ligated into NcoI/BstEII-digested S.L.ST.gG.P. This intermediate plasmid, pSPgTM2.P, was then digested with NcoI and ligated to a synthetic oligonucleotide linker containing NcoI compatible ends (sense strand CATGAACGGATCATC). The resultant plasmid encodes N terminus residues MNGSSMVN followed by CFTR residues Ala107-Asn186 followed by the P reporter.

All constructs were sequenced throughout PCR-amplified or -mutagenized cDNA to verify the presence of appropriately engineered mutations and the absence of inadvertent PCR errors.

Transcription and Translation-- mRNA was transcribed in vitro with SP6 RNA polymerase (New England Biolabs) using 2-4 µg of plasmid DNA in a 10-µl volume at 40 °C for 1 h as described (11). Transcription reaction mixture was translated directly in a transcription-linked rabbit reticulocyte lysate (RRL) system as described previously (18). Where indicated, canine pancreas microsomes (final concentration, 8.0 A280) and/or the tripeptide Ac-Asn-Tyr-Thr (final concentration, 0.2 mM) were added at the start of translation. Prior to proteolysis, chains synthesized on truncated mRNA (e.g. lacking a termination codon) were released from ribosomes by incubation in 1 mM puromycin at 24 °C for 10-15 min. For oocyte expression 50 µCi of Tran35S-label (ICN Pharmaceuticals, Irvine, CA) (0.5 µl of a 10 × concentrated mixture) was added to 2 µl of transcription mixture and injected into mature Xenopus laevis oocytes (XO) (50 nl/oocyte). Oocytes were incubated at 18 °C for 3-4 h and homogenized on ice in 10 volumes of 0.25 M sucrose, 50 mM KAc, 5 mM MgAc2, 1.0 mM dithiothreitol, 50 mM Tris (pH 7.5). Prior to proteolysis, CaCl2 was added to 10 mM final concentration.

Protease Digestion-- Proteinase K (PK) was added to RRL translation mixture or aliquots of oocyte homogenate (0.2 mg/ml final concentration) in the presence or absence of 1% Triton X-100 and incubated on ice for 1 h (18). Residual protease was inactivated by adding phenylmethylsulfonyl fluoride (10 mM) and rapidly mixing with 10 volumes of 1% SDS, 0.1 M Tris, pH 8.0 (preheated to 100 °C). Oocyte samples were subsequently diluted in >10 volumes of buffer A (0.1 M NaCl, 1% Triton X-100, 2 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, and 0.1 M Tris, pH 8.0), incubated at 4 °C for 2-4 h, centrifuged at 14,000 × g for 15 min, and the supernatants were used for subsequent immunoprecipitation.

Immunoprecipitation and Autoradiography-- Antiprolactin antisera (ICN Immunologicals, Costa Mesa, CA) was added to RRL translation mixtures diluted in 0.5 ml of buffer A (1:1000 dilution) or to clarified oocyte homogenates. After a 10-30 min preincubation, 5 µl of protein A Affi-Gel (Bio-Rad) was added, and the samples were mixed at 4 °C for 2-10 h prior to washing three times with buffer A and twice with 0.1 M NaCl, 0.1 M Tris, pH 8.0. Samples were analyzed by SDS-PAGE, EN3HANCE (NEN Life Science Products) fluorography, and autoradiography. Autoradiograms were digitized with an AGFA Studio Scan II, and band intensities were quantified on unmodified images using Adobe Photoshop software as described previously (17, 20). Several different film exposure times were compared to ensure that determinations remained within the linear range.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

CFTR-TM1 Functions as an Inefficient Signal Sequence to Direct CFTR Translocation-- To define the translocation activity of CFTR-TM1, CFTR cDNA encoding residues Met1 through Ser118 was engineered in the N-terminal direction to a previously defined translocation reporter (P) (18) in a series of WT and mutant plasmids (Fig. 1). Plasmids were expressed in reticulocyte lysate supplemented with ER-derived canine pancreas microsomes, and topology of the P reporter was determined by its accessibility to exogenously added PK (18). Polypeptides generated from WT plasmid TM1.P (Fig. 1, lane 1, downward arrow) gave rise to several prolactin-reactive fragments following PK digestion in the absence, but not the presence, of non-denaturing detergent (lanes 2 and 3, arrows). In these chains, the P reporter thus resided in the microsome (e.g. ER) lumen. Some of these translocated fragments were generated from full-length chains in which TM1 spanned the membrane with its N terminus oriented toward the cytosol (28-kDa band, lane 2, downward arrows), while smaller PK-protected fragments were also observed prior to protease digestion (19-kDa band, lanes 1 and 2, upward arrows; more evident in lanes 14 and 17). These latter fragments were dependent on the addition of ER membranes (data not shown) and were likely generated by signal peptidase cleavage of nascent chains at cryptic recognition sites unmasked by truncation of TM2 as has been observed previously for similar constructs (17, 18, 20, 36). In contrast to WT chains, no protease-protected fragments were observed for TM1.P(G85E) or TM1.P(G91R) chains, demonstrating that these inherited cystic fibrosis-related mutations abolished the ability of TM1 to direct translocation of the P reporter (lanes 4-6 and 7-9, respectively).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Signal sequence activity of TM1. Sequence of CFTR TM1 and predicted boundaries of TM segment and mutant residues are indicated. Plasmids TM1.P, TM1.P(G85E), TM1.P(G91R), TM1.P(E92A), TM1.P(K95A), and TM1.P(E92A/K95A) were expressed in rabbit reticulocyte lysate supplemented with canine pancreas microsomal membranes (A) or in microinjected Xenopus oocytes (B) as described under "Materials and Methods." PK digestion was performed in the presence or absence of detergent (det) as indicated, and samples were immunoprecipitated with antiprolactin antisera prior to SDS-polyacrylamide gel electrophoresis. Full-length chains and PK-protected fragments generated by full-length chains are indicated by downward arrows. Translocated fragments generated by signal peptidase cleavage are indicated by upward arrows. Full-length chains, 28-kDa fragments, and signal peptidase-cleaved fragments contain six, five, and four methionine residues as deduced from CFTR primary sequence. Additional minor bands observed in RRL prior to PK digestion (lanes 1, 4, 7, 10, 13, 16) likely represent incomplete synthesis of partial length chains. Topology of the translocated chains is diagrammed. The shaded oval and hatched box represent TM segment and P reporter, respectively.

Quantitation of autoradiograms in Fig. 1 and correction for methionine content of fragments revealed that CFTR-TM1 was significantly less efficient at directing P reporter translocation than other polytopic protein-derived signal sequences that have been examined in this same context. The P reporter resided in the ER lumen in only 12% of newly synthesized WT TM1.P chains compared with 80-95% translocation efficiency previously reported by us and others (15-18, 21). Because all TM1-flanking residues were included in these constructs, translocation efficiency of TM1 could not be explained by removal of topogenic information. Similarly, the P reporter has been shown to faithfully follow topogenic information in a wide variety of contexts and would not be expected to negatively influence TM1 activity (11). Rather, it seemed plausible that TM1 either lacked translocation specificity (i.e. some chains spanned the membrane in the opposite orientation with their N terminus translocated) or that primary structural features within TM1, such as charged residues Glu92 and/or Lys95, limited its signal sequence activity. We therefore examined translocation efficiency of polypeptides generated from plasmids TM1.P(E92A), TM1.P(K95A) and TM1.P(E92A/K95A). As shown in Fig. 1A, lanes 10-18, the E92A and E92A/K95A mutations both improved TM1 signal sequence activity (43% and 79% of P translocated, respectively), whereas the K95A mutation by itself had little effect (10% of P translocated). This suggested that residues Glu92 and Lys95 within the hydrophobic core of TM1 directly reduced TM1 C terminus translocation activity and prevented TM1 from achieving a stable transmembrane orientation.

To address whether the weak TM1 signal sequence activity observed in vitro might be due to artifacts introduced by the reconstituted cell free RRL system, we also examined TM1 signal sequence activity in microinjected X. laevis oocytes (Fig. 1B). These in vivo studies confirmed results obtained in vitro and demonstrated the following: (i) signal sequence activity of WT TM1 was significantly impaired (only 28% of chains translocated); (ii) G85E and G91R mutations essentially abolished TM1 signal sequence activity (<5% of chains translocated); and (iii) E92A and E92A/K95A mutations improved TM1 signal sequence activity (36% and 70% of chains translocated, respectively).

CFTR-TM2 Encodes Signal Sequence Activity Complimentary to TM1-- If CFTR utilized a strict cotranslational mechanism of assembly, then the weak signal sequence activity of WT TM1 would result in failure of most CFTR chains to translocate and assemble properly in the ER membrane. This, however, was not the case because greater than 70% of WT as well as G85E and G91R chains achieved their correct N terminus topology in the ER membrane ((33) and Fig. 4). These results suggested that topogenic information in addition to TM1 must function to ensure correct CFTR topology. We therefore examined the signal sequence activity of TM2 using the plasmid ggTM2.P, which encodes two (engineered) N-linked glycosylation consensus sites 12 and 18 residues from the membrane-spanning segment, followed by TM2 together with its flanking sequences (CFTR residues Ala107-Asn186), followed by the P reporter (diagrammed in Fig. 2). For initial experiments, plasmid ggTM2.P was truncated at codon Asn186 (Fig. 2A). N-linked glycosylation of ggTM2 polypeptides was demonstrated by the appearance of a slower migrating band in the presence of microsomal membranes but not in the presence of a peptide inhibitor (AcNYT) of oligosaccharyltransferase (Fig. 2A, downward arrow). N terminus glycosylation was also observed in the presence of microsomal membranes for ggTM2.P chains containing the P reporter (65% of chains glycosylated) (Fig. 2B). Both glycosylated and unglycosylated full-length ggTM2.P chains were accessible to protease (Fig. 2C, lanes 1-3), and immunoprecipitation with antiprolactin antisera confirmed that the P reporter was cytosolic (lanes 4-6). Thus TM2 directed an N-trans (or type I) transmembrane topology in which N terminus flanking residues resided in the ER lumen and C terminus residues faced the cytosol. This topology is consistent with the predicted orientation for TM2 in native CFTR (37, 38).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   TM2 signal sequence activity. Sequence of CFTR TM2 and location of engineered N-linked glycosylation consensus sites (NGS and NAS) are indicated. Plasmid constructs are schematically diagrammed above autoradiograms. Vertical lines denote potential glycosylation sites. In panel A, plasmid ggTM2.P (lanes 1-3) was truncated at BstEII and translated in RRL supplemented with microsomal membranes and an inhibitor of oligosaccharyltransferase (Acceptor Pep., AcNYT) as indicated. The downward arrow indicates glycosylated chains (lane 2). B, translation of ggTM2.P (lanes 1-3) as shown in panel A. (C) PK digestion of chains generated from plasmid ggTM2.P. Total translation products (lanes 1-3) and translation products immunoprecipitated with antiprolactin antisera (lanes 4-6). Topology of TM2 is indicated beneath the autoradiograms.

For the experiments outlined above, microsomal membranes were titrated to achieve 90-95% translocation efficiency based on protease protection of control secretory proteins (data not shown). However, estimating translocation efficiency by N-linked glycosylation is more difficult because utilization of consensus sites is context dependent. Lack of ggTM2.P glycosylation might therefore have resulted either from failure of the chain to translocate into the microsome lumen or failure of a particular translocated consensus site to be utilized by oligosaccharyltransferase. For readily accessible sites, glycosylation efficiency of our microsomal membranes is approximately 85-90% of translocated chains (18). Therefore, the 65% glycosylation efficiency observed for ggTM2.P chains indicates that TM2 is efficient in translocating N terminus flanking residues and directing a specific N-trans or type I transmembrane topology complimentary to that of TM1. It should be noted that the TM1.P constructs tested in Fig. 1 also encoded a potential N-linked glycosylation consensus site 33 residues N-terminal to the putative membrane-spanning segment. Whereas lack of glycosylation of TM1.P chains does not rule out the possibility that some chains were oriented with their N terminus in the ER lumen (for reasons stated above), the different glycosylation and proteolysis results observed for polypeptides TM1.P and ggTM2.P strongly indicate that TM1 and TM2 encode distinct and complimentary translocation specificities.

To better define the role of TM2 in directing CFTR topology, we attempted to decrease TM2 signal sequence activity by introducing three mutations previously identified in cystic fibrosis patients (G126D, Delta E115, and E116K) (39). These mutations were engineered alone or in combination into the plasmid ggTM2.P, and topology of the resulting chains was determined in RRL (Fig. 3). Mutations Delta E115 or E116K had only minor effects on TM2 signal sequence activity based on the fraction of glycosylated chains (Fig. 3A, lanes 1-6). However, the double mutations E115K/E116K, E116K/G126D and the triple mutation E115K/E116K/G126D all reduced N-linked glycosylation to approximately 20% of chains, a 65-70% reduction from WT levels (Fig. 3A, lanes 7-15). Because the location and context of glycosylation sites were unchanged in these mutants, it was unlikely that accessibility of consensus sites to oligosaccharyltransferase was altered. Rather, these results suggest a corresponding decrease in N terminus translocation efficiency by mutant TM2.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Mutagenesis of TM2 signal sequence activity. Mutations at positions Glu115 (E115), Glu116 (E116), and/or Gly126 (G126) were engineered into the plasmid ggTM2.P at the sites indicated, and plasmids were expressed in RRL as described in Fig. 2. A, glycosylated chains are indicated by downward arrows. B, immunoprecipitation of proteolysis products using antiprolactin antisera. Upward arrows indicate prolactin reactive protected chains resulting from translocation of C-terminal flanking residues by TM2. Topology of chains is diagrammed.

PK digestion of mutant ggTM2.P chains (Delta E115, E116K, and E115K/E116K) indicated that the introduction of basic residues flanking the N terminus of TM2, altered TM2 translocation specificity and enabled TM2 to translocate C terminus flanking sequences in a subset of chains. This was particularly evident for the E115K/E116K mutant (Fig. 3B, lanes 1-9, upward arrows), consistent with the proposed role of basic flanking residues in determining signal sequence translocation specificity (19, 40-45). For the remaining two mutants, E116K/G126D and E115K/E116K/G126D, little or no translocation of the P reporter was observed (lanes 10-15).

TM1 and TM2 Both Participate in CFTR N Terminus Assembly-- Previously we showed that WT CFTR chains truncated at residue Asn186 efficiently achieved a topology in RRL in which TM1 and TM2 each spanned the membrane with their N and C termini, respectively, in the cytosol (33). This topology is consistent with the translocation specificities of TM1 and TM2 (Figs. 1 and 2) as well as the proposed orientation of native CFTR (37, 38). CFTR cDNA encoding mutations, Delta E115, E116K, E115K/E116K, E116K/G126D or E115K/E116K/G126D was therefore truncated at codon Asn186, and the topology of chains was determined in RRL (Fig. 4). Plasmids encoding TM1 mutations, G85E and G91R (33), were also included for comparison. Truncated polypeptides migrated at 22-22.5 kDa (lane 1, downward arrow). The nature of the doublet is unclear but may reflect a relative inefficiency of ribosomes to read to the end of the truncated mRNA, or alternatively, puromycin incorporation in a subset of chains. Following PK digestion, both WT and mutant chains yielded a 17-kDa protease-protected fragment (Fig. 4, upward arrows) which has been shown to contain TM1, TM2, and the first extracellular loop (33). The size of these protected fragments suggests that they contain 40-60% of the total methionine residues present in undigested chains (Met1, Met155, and possibly Met152 are digested, whereas Met82 and Met150 are likely protected). Quantitation of eleven different experiments for truncated WT chains revealed that 42% (range, 31-55%) of total 35S was protected from PK. Thus, CFTR N terminus assembly was greater than 70% efficient in RRL (depending on the precise site of PK cleavage).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of TM2 mutations on N terminus topology. Plasmids encoding WT and mutant CFTR chains were truncated at codon Asn186, expressed in RRL, and digested with PK as described in Fig. 1. A, total translation products before and after PK digestion. Truncated chains migrated as a 22- and 22.5-kDa doublet (lane 1, downward arrow), which was converted to a 17-kDa protected fragment following PK digestion (upward arrows). B, translocation of the TM1-2 peptide loop normalized to the efficiency observed for WT chains was calculated as the ratio of (17 kDa/22 kDa)MUTANT/(17 kDa/22 kDa)WT.

Fig. 4B shows the translocation efficiency of chains that contain a single mutation in either TM1 or TM2 relative to WT chains. For comparison purposes, the translocation efficiency of WT chains was tested in each experiment and normalized to 1. TM2 was independently capable of translocating the CFTR N terminus in the absence of a functional TM1 signal sequence (Fig. 4, lanes 4-9). However, TM2 mutations E116K/G126D and E115K/E116K/G126D had a relatively minor but reproducible effect on CFTR N terminus topology, 82 and 79% of WT translocation activity, respectively (Fig. 4B, lanes 16-24 and Fig. 5, A and B). When the TM1 mutation G85E was introduced into chains containing E116K/G126D or E115K/E116K/G126D mutations, translocation efficiency was further reduced to 45% and 48% of WT levels, respectively (Fig. 5, A and B). This level of translocation correlated well with the residual TM2 signal sequence activity in these chains and indicated that WT TM1 was able to partially compensate for the loss of TM2 signal sequence activity. TM1, however, was unable to ensure that all CFTR chains were correctly oriented in the ER membrane in the absence of a fully functional TM2 signal sequence. This conclusion was further supported by the observation that improving TM1 signal sequence activity using the mutant E92A/K95A completely restored N terminus translocation in TM2 mutants (Fig. 5). Thus an efficient signal sequence in either the TM1 or the TM2 position was sufficient to ensure proper CFTR N terminus topology.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 5.   Role of TM1 and TM2 in CFTR N terminus topogenesis. CFTR chains encoding TM1 and/or TM2 mutations (indicated) were truncated at N186, and topology was determined as in Fig. 4. Results shown are averages from three separate consecutive experiments (±S.E.). Translocation efficiencies were normalized to WT chains in each experiment as in Fig. 4.

We also observed that the E115K/E116K mutation, which partially reversed TM2 translocation specificity, was more disruptive than other TM2 mutations. Only 55% of truncated E115K/E116K chains achieved correct topology (Fig. 5C), and the G85E mutation had little effect on these chains. Furthermore, even an efficient TM1 signal sequence (E92A/K95A) restored translocation efficiency to only 69% of WT levels. Thus when topogenic information encoded within TM2 directly conflicted with the information encoded within TM1, these determinants appeared to exhibit an antagonistic effect on transmembrane assembly.

TM2 Directs Posttranslational Assembly of CFTR N Terminus-- Our results predict that as TM2 emerges from the ribosome it posttranslationally directs topology of TM1 and the TM1-2 peptide loop. However it was unclear whether TM2-mediated translocation might require earlier (e.g. cotranslational) membrane targeting by upstream residues prior to the initiation of translocation. We therefore tested whether TM2 was able to direct translocation of presynthesized cytosolic nascent chains by truncating CFTR cDNA at codon Asn186 and translating in RRL in the absence of microsomal membranes. Translation was then terminated by addition of cyclohexamide, and the RRL mixture was then incubated with microsomal membranes prior to PK digestion. As shown in Fig. 6A, CFTR chains containing WT TM1 and TM2 posttranslationally achieved correct transmembrane topology as evidenced by the presence of 17-kDa protease-protected fragments (upward arrows). Furthermore, the efficiency of posttranslational translocation was relatively unaffected by mutations that disrupted signal sequence activity of either TM1 or TM2 alone (lanes 4-9 and 13-15) but was decreased when both sequences were mutated together (lanes 10-12 and 16-18). Thus TM1 and TM2 appear to cooperate similarly in directing CFTR topology regardless of whether translation was performed in the presence or absence of microsomal membranes. As shown in Fig. 6B, however, translocation of the TM1-2 peptide loop was markedly decreased (by >80%) if nascent CFTR chains were released from ribosomes prior to addition of ER microsomes.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 6.   Posttranslational translocation of TM2. WT and mutant CFTR chains were truncated at Asn186 and expressed in RRL in the absence of microsomal membranes (A). After 30 min, cyclohexamide (0.1 mM) and microsomal membranes were added, and samples were incubated for an additional 30 min prior to PK digestion. In panel B, samples were treated as in panel A except that at T = 30 min, puromycin (1 mM) was added with cyclohexamide; at T = 45 min, microsomal membranes were added, and at T = 75 min, samples were treated with PK.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

CFTR assembly and maturation requires coordinated folding events in the cytosol, ER lumen, and lipid bilayer. In aqueous environments, CFTR folding appears to be facilitated by cellular chaperones including calnexin (46) and hsp70 (47), which repetitively bind to incompletely or improperly folded chains. This ATP dependent process is believed to (i) slow protein folding, (ii) correct off-pathway folding intermediates, and/or (iii) maintain a transient "folding competent" state until protein synthesis and assembly has been completed (reviewed in Refs. 48 and 49). Transmembrane domains of polytopic proteins must also fold properly, and one key aspect of this process is the acquisition of correct topology and association with membrane lipids, here referred to as topogenesis. As with aqueous polypeptide domains, topogenesis is facilitated by a complex set of cellular proteins. These proteins, collectively termed the translocon (50, 51), interact with topogenic determinants to direct protein translocation across the ER membrane and integration into the lipid bilayer (18, 26, 27, 52-54).

Because translation and translocation are usually coupled vectorially at the ER membrane, polytopic protein topogenesis has been proposed to occur through the sequential action of alternating signal (anchor) and stop transfer sequences (1). Consistent with this hypothesis, cotranslational topogenesis has been demonstrated for several eukaryotic polytopic proteins such as the erythrocyte anion transporter and the mercury-insensitive water channel where topology of N terminus TM segments is established even before the synthesis of C terminus TM segments has been completed (7, 21). However, cotranslational assembly requires each individual topogenic determinant to act independently, sequentially, and efficiently, because a mistake at any point in topogenesis will potentially misdirect a region of polypeptide into the wrong cellular compartment. In the current study we provide evidence both in vitro and in vivo that the initial topogenic determinant of CFTR, TM1, is quite inefficient at directing nascent chain translocation due to the presence of specific charged residues within its hydrophobic core. Thus, if CFTR solely utilized a cotranslocational mechanism of topogenesis, chains failing to target and/or translocate via TM1 would fail to assemble into the membrane. This was not the case, however, because WT CFTR chains achieved their correct topology. Furthermore, even chains containing a completely defective TM1 signal sequence (G85E and G91R mutants) were properly oriented in the membrane but only if a functional TM2 signal sequence was present.

Our data indicate therefore that CFTR utilizes two independent and redundant topogenesis pathways at the ER membrane, each of which contributes to directing correct N terminus topology (Fig. 7). In one pathway, TM1 emerges from the ribosome, targets CFTR chains to the ER membrane, initiates translocation of C terminus flanking sequences, and spans the membrane in a C-trans (type II) orientation. In this subset of CFTR chains, translocation is subsequently terminated by TM2, and topology is thus established in a cotranslational manner. However, when TM1 fails to translocate the chain, topogenic information encoded within TM2 provides a second chance for chains to acquire their correct transmembrane orientation. In this case, we propose that TM2 initiates translocation of its own N terminus flanking residues in a manner similar to an N-trans (type I) signal anchor sequence (2, 3, 14, 55). The unusual feature of this process is that TM1 is posttranslationally directed into the translocon channel from a cytosolic orientation where it then terminates translocation and establishes its proper membrane-spanning topology. The consequence of such a mechanism is that the direction of nascent chain movement through the translocation channel is different in these two pathways. In cotranslational translocation (e.g. conventional pathway), the chain moves into the ER lumen from N to C terminus as it leaves the ribosome, whereas in the posttranslational pathway the chain enters the ER lumen from C to N terminus, presumably from a location in the cytosol.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 7.   Alternate assembly pathways for CFTR N terminus topogenesis. Schematic representation of the assembly pathways utilized by CFTR. Ribosomes (open circles), TM segments (shaded ovals), translocon channel (black rectangles), and lipid bilayer are diagrammed. A, conventional cotranslational pathway involving sequential translocation activities of TM1 and TM2 functioning as signal and stop transfer sequences, respectively. B, when TM1 fails to initiate translocation, posttranslational translocation of the TM1-2 peptide loop is initiated by TM2. In this case, transmembrane topology of TM1 is established by posttranslational termination of translation.

Because protein topogenesis is a multistep process involving signal recognition particle binding (56), ER targeting (57), signal recognition particle release (58), translocon gating, translocation initiation (59), and membrane integration (52), several details of CFTR topogenesis remain unknown. It is possible that residues Glu92 and/or Lys95 within TM1 interfere with ER membrane targeting. If this were the case, then TM1 would fail to bind signal recognition particle and emerge from the ribosome directly into the cytosol. TM2 would therefore be required to perform all targeting and translocation events. Alternatively, if TM1 were able to dock ribosomes at the ER membrane but failed to initiate translocation (i.e. failed to effectively gate the translocon channel), then TM2 would be required only to initiate translocation of chains already in the physical vicinity of the translocon. A third possibility is that TM1 might initiate translocation of CFTR chains but independently be unable to close the translocon channel, allowing the P reporter to fall back into the cytosol where it would appear to have never translocated (60). In this case, TM2 might act to stabilize an otherwise transient transmembrane orientation of TM1. This is an important consideration because CFTR-TM1, like MDR1-TM1, is unable to independently integrate the nascent chain into the lipid bilayer (18),2 implying that neither of these sequences completely disengages from the translocon and/or its associated proteins (52). However, because MDR1-TM1 efficiently directed nascent chain translocation despite its failure to integrate, lack of integration per se does not necessarily result in retrograde translocation. Furthermore, unlike MDR1 where TM1 and TM2 together are sufficient for integration (18), stable membrane integration of CFTR requires synthesis of at least four TM segments.2 Thus if TM2 acted primarily to prevent TM1 from falling out of the translocon, it would likely do so in the context of ER translocation machinery. Given the limitations of the current study, we cannot rule out the possibility that such a mechanism might contribute in some manner to the cooperativity between TM1 and TM2 observed in CFTR assembly.

It should also be noted that despite the widespread and accepted use of RRL in defining mechanisms of translocation and membrane integration, it is always possible that in vitro systems may introduce potential artifacts that do not reflect in vivo assembly pathways. This may be particularly important for proteins such as CFTR with specialized requirements for assembly. In this regard, our analyses of TM1 signal sequence activity using an in vivo Xenopus oocyte expression system confirmed all of the essential features observed in vitro, namely the inefficient activity of TM1 and the effects charged residues Glu85, Arg91, Glu92, and Lys95. These results, together with recent evidence that up to 100% of newly synthesized CFTR protein matures in Xenopus oocytes (33), argues that both in vivo and in vitro the weak TM1 signal sequence activity must be compensated by topogenic information encoded within TM2 to ensure efficient and proper N terminus assembly.

Why might CFTR have evolved this unusual mechanism of topogenesis? One possibility is that such a mechanism arose from conflicting structural requirements within TM1 for protein assembly (at the ER membrane) and for protein function (elsewhere in the cell). In this regard, charged residues within TM segments are known to influence protein topogenesis, folding, and oligomerization (40, 42, 43, 61, 62), as well as structural properties important for ion conduction, selectivity, and gating (63-66). Consistent with this view, we observed that full-length CFTR encoding E92A or the double mutation, E92A/K95A, exhibited markedly reduced chloride channel activity when expressed in Xenopus oocytes.3 In addition, scanning cysteine accessibility studies have revealed that Lys95 resides on a hydrophilic surface of TM1 and likely faces the CFTR chloride channel pore, whereas Glu92 appears to face 40° away from the pore surface, suggesting that it contributes to ionic interactions within the plane of the bilayer (67). Thus it seems likely that functional requirements for charged residues Glu92 and/or Lys95 within mature CFTR necessitated the presence of redundant topogenic information encoded by TM2 to ensure efficient protein topogenesis. It is interesting, however, that unlike other ATP binding cassette transporters, up to 80% of WT CFTR protein expressed in mammalian cells may be degraded prior to exit from the ER (68). This is proposed to result from inefficient folding of WT protein and subsequent degradation of CFTR through a ubiquitin proteasome-mediated pathway (69, 70). Why such a complex mechanism for ensuring fidelity of TM1-2 topogenesis should have evolved in light of the overall inefficient folding of full-length CFTR, and whether these two aspects of CFTR biogenesis are related, remain unanswered questions.

Finally, cooperativity between topogenic determinants has also been described for additional polytopic proteins such as the E. coli protein lac permease (29), the yeast protein Sec61p (30), and others. In the case of lac permease a charged residue critical for lactose transport, Arg302, markedly decreased TM9 signal sequence activity and led the authors to propose that a salt bridge between Arg302 and Glu325 (within TM10) allowed these helices to insert into the membrane as a pair. Whereas this observation resembles the behavior of TM1 and TM2 from CFTR, our data support a slightly different model in which CFTR topogenesis is directed by two distinct signal sequences in either a co- or posttranslational manner. Our model may also explain the observations by Bayle et al. (24), in which the predicted fifth and sixth membrane-spanning segments (H5 and H6) from the rat sarcoplasmic and endoplasmic reticulum calcium ATPase failed to exhibit the expected signal and stop transfer sequence activities required for cotranslational topogenesis. Together these studies suggest that the alternate topogenesis pathway such as those demonstrated for CFTR may represent a more general mechanism utilized by diverse polytopic proteins with specialized needs for transmembrane assembly.

    ACKNOWLEDGEMENTS

The authors thank Kenneth Moss for technical assistance, William Gresh, Drs. Michael Marks, and Carol Deutsch for helpful comments.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA01614, DK51818, and GM53457 and the Cystic Fibrosis Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to this work.

§ To whom correspondence should be addressed: Dept. of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-898-0953; Fax: 215-573-8590.

1 The abbreviations used are: ER, endoplasmic reticulum; CFTR, cystic fibrosis transmembrane conductance regulator; PCR, polymerase chain reaction; WT, wild type; TM, transmembrane segment; RRL, rabbit reticulocyte lysate; PK, proteinase K.

2 William R. Skach, unpublished observations.

3 K. Foskett and W. Skach, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Blobel, G. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 1496-1500[Abstract]
  2. Wickner, W. T., and Lodish, H. F. (1985) Science 230, 400-407[Medline] [Order article via Infotrieve]
  3. Skach, W., and Lingappa, V. (1993) in Mechanisms of Intracellular Trafficking and Processing of Pro-proteins (Loh, Y. P., ed), pp. 19-77, CRC Press Inc., Boca Raton, FL
  4. Lingappa, V. R., Devillers-Thiery, A., and Blobel, G. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 2432-2436[Abstract]
  5. Rothman, J. E., and Lodish, H. F. (1977) Nature 269, 775-780[Medline] [Order article via Infotrieve]
  6. Lingappa, V. R., Lingappa, J. R., Prasad, R., Ebner, K. E., Blobel, G. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 2338-2342[Abstract]
  7. Braell, W. A., and Lodish, H. F. (1982) Cell 28, 23-31[Medline] [Order article via Infotrieve]
  8. Brown, D., and Simoni, R. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1674-1678[Abstract]
  9. Borel, A., and Simon, S. (1996) Biochemistry 35, 10587-10594[CrossRef][Medline] [Order article via Infotrieve]
  10. Lipp, J., Flint, N., Haeuptle, M. T., Dobberstein, B. (1989) J. Cell Biol. 109, 2013-2022[Abstract]
  11. Rothman, R. E., Andrews, D. W., Calayag, M. C., Lingappa, V. R. (1988) J. Biol. Chem. 263, 10470-10480[Abstract/Free Full Text]
  12. Wessels, H., and Spiess, M. (1988) Cell 55, 61-70[CrossRef][Medline] [Order article via Infotrieve]
  13. Audigier, Y., Friedlander, M., and Blobel, G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5783-5787[Abstract]
  14. Friedlander, M., and Blobel, G. (1985) Nature 318, 338-343[Medline] [Order article via Infotrieve]
  15. Chavez, R. A., and Hall, Z. W. (1991) J. Biol. Chem. 266, 15532-15538[Abstract/Free Full Text]
  16. Chavez, R., and Hall, Z. (1992) J. Cell Biol. 116, 385-393[Abstract]
  17. Skach, W., and Lingappa, V. (1994) Cancer Res. 54, 3202-3209[Abstract]
  18. Skach, W., and Lingappa, V. (1993) J. Biol. Chem. 268, 23552-23561[Abstract/Free Full Text]
  19. Zhang, J.-T., Lee, C., Duthie, M., and Ling, V. (1995) J. Biol. Chem. 270, 1742-1746[Abstract/Free Full Text]
  20. Skach, W., Shi, L.-B., Calayag, M. C., Frigeri, A., Lingappa, V., Verkman, A. (1994) J. Cell Biol. 125, 803-815[Abstract]
  21. Shi, L.-B., Skach, W., Ma, T., and Verkman, A. (1995) Biochemistry 34, 8250-8256[Medline] [Order article via Infotrieve]
  22. Tam, L., Loo, T., Clarke, D., and Reithmeier, R. (1994) J. Biol. Chem. 269, 32542-32550[Abstract/Free Full Text]
  23. Melchers, K., Weitzenegger, T., Buhmann, A., Steinhilber, W., Sachs, G., and Schaefer, K. (1996) J. Biol. Chem. 271, 446-457[Abstract/Free Full Text]
  24. Bayle, D., Weeks, D., and Sachs, G. (1995) J. Biol. Chem. 270, 25678-25684[Abstract/Free Full Text]
  25. Anderson, D., Walter, P., and Blobel, G. (1982) J. Cell Biol. 93, 501-506[Abstract]
  26. Mothes, W., Heinrich, S., Graf, R., Nilsson, I., von Heijne, G., Brunner, J., Rapoport, T. (1997) Cell 89, 523-533[Medline] [Order article via Infotrieve]
  27. Borel, A., and Simon, S. (1996) Cell 85, 379-389[Medline] [Order article via Infotrieve]
  28. Calamia, J., and Manoil, C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4937-4941[Abstract]
  29. Calamia, J., and Manoil, C. (1992) J. Mol. Biol. 224, 539-543[Medline] [Order article via Infotrieve]
  30. Wilkinson, B., Critchley, A., and Stirling, C. (1996) J. Biol. Chem. 271, 25590-25597[Abstract/Free Full Text]
  31. Mueckler, M., and Lodish, H. F. (1986) Cell 44, 629-637[Medline] [Order article via Infotrieve]
  32. Zhang, J.-T., Chen, M., Foote, C., and Nicholson, B. (1996) Mol. Biol. Cell 7, 471-482[Abstract]
  33. Xiong, X., Bragin, A., Widdicombe, J., Cohn, J., and Skach, W. (1997) J. Clin. Invest. 100, 1079-1088[Abstract/Free Full Text]
  34. Hasegawa, H., Skach, W., Baker, O., Calayag, M. C., Lingappa, V., Verkman, A. (1992) Science 258, 1477-1479[Medline] [Order article via Infotrieve]
  35. Ho, N., Hunt, H., Horton, R., Pullen, J., and Pease, P. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
  36. Akiyama, Y., Inada, T., Nakamura, Y., and Ito, K. (1990) J. Bacteriol. 172, 2888-2893[Medline] [Order article via Infotrieve]
  37. Denning, G., Ostedgaard, L., Cheng, S., Smith, A., and Welsh, M. (1992) J. Clin. Invest. 89, 339-349[Medline] [Order article via Infotrieve]
  38. Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Collins, F. S., Tsui, L.-C. (1989) Science 245, 1066-1072[Medline] [Order article via Infotrieve]
  39. Cystic Fibrosis Analysis Consortium (1997) Cystic Fibrosis Mutation Data Base, www.genet.sickkids.on.ca/cftr
  40. Parks, G. D., and Lamb, R. A. (1991) Cell 64, 777-787[Medline] [Order article via Infotrieve]
  41. Szczesna-Skorupa, E., and Kemper, B. (1989) J. Cell Biol. 108, 1237-1243[Abstract]
  42. Szczesna-Skorupa, E., Browne, N., Mead, D., and Kemper, B. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 738-742[Abstract]
  43. Hartmann, E., Rapoport, T. A., and Lodish, H. F. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 5786-5790[Abstract]
  44. von Heijne, G., and Gavel, Y. (1988) Eur. J. Biochem. 174, 671-678[Abstract]
  45. von Heijne, G. (1986) EMBO J. 5, 3021-3027
  46. Pind, S., Riordan, J., and Williams, D. (1994) J. Biol. Chem. 269, 12784-12788[Abstract/Free Full Text]
  47. Yang, Y., Janach, S., Cohn, J., and Wilson, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9480-9484[Abstract]
  48. Gething, M. J., and Sambrook, J. (1992) Nature 355, 33-45[CrossRef][Medline] [Order article via Infotrieve]
  49. Rothman. (1989) Cell 59, 591-601[Medline] [Order article via Infotrieve]
  50. Walter, P., and Lingappa, V. R. (1986) Annu. Rev. Cell Biol. 2, 499-516[CrossRef]
  51. Gilmore, R. (1993) Cell 75, 615-630[Medline] [Order article via Infotrieve]
  52. Do, H., Falcone, D., Lin, J., Andrews, D., and Johnson, A. (1996) Cell 85, 369-378[Medline] [Order article via Infotrieve]
  53. Rapoport, T., Rolls, M., and Jungnickel, B. (1996) Curr. Opin. Cell Biol. 8, 499-504[CrossRef][Medline] [Order article via Infotrieve]
  54. Laird, V., and High, S. (1997) J. Biol. Chem. 272, 1983-1989[Abstract/Free Full Text]
  55. Williams, M. A., and Lamb, R. A. (1986) Mol. Cell. Biol. 6, 4317-4328[Medline] [Order article via Infotrieve]
  56. Walter, P., Ibrahimi, I., and Blobel, G. (1981) J. Cell Biol. 91, 545-550[Abstract]
  57. Walter, P., and Blobel, G. (1981) J. Cell Biol. 91, 551-556[Abstract]
  58. Connolly, T., Rapiejko, P. J., and Gilmore, R. (1991) Science 252, 1171-1173[Medline] [Order article via Infotrieve]
  59. Jungnickel, B., and Rapoport, T. (1995) Cell 82, 261-270[Medline] [Order article via Infotrieve]
  60. Ooi, C., and Weiss, J. (1992) Cell 71, 87-96[Medline] [Order article via Infotrieve]
  61. Cutler, D. F., Melancon, P., and Garoff, H. (1986) J. Cell Biol. 102, 902-910[Abstract]
  62. Cosson, P., Lankford, S., Bonifacino, J., and Klausner, R. (1991) Nature 351, 414-416[CrossRef][Medline] [Order article via Infotrieve]
  63. Anderson, M. P., Gregory, R. J., Thompson, S., Souza, D. W., Paul, S., Mulligan, R. C., Smith, A. E., Welsh, M, J. (1991) Science 253, 202-204[Medline] [Order article via Infotrieve]
  64. Papazian, D., Shao, X., Seoh, S., Mock, A., Huang, Y., and Wainstock, D. (1995) Neuron 14, 1293-1301[Medline] [Order article via Infotrieve]
  65. Yang, N., George, A., and Horn, R. (1996) Neuron 16, 113-122[Medline] [Order article via Infotrieve]
  66. Perozo, E., Santacruz-Toloza, L., Stefani, E., Bezanilla, F., and Papazian, D. (1994) Biophys. J. 66, 345-354[Abstract]
  67. Akabas, M., Kaufmann, C., Cook, A., and Archdeacon, P. (1994) J. Biol. Chem. 269, 14865-14868[Abstract/Free Full Text]
  68. Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., Smith, A. E. (1990) Cell 63, 827-834[Medline] [Order article via Infotrieve]
  69. Ward, C., and Kopito, R. (1994) J. Biol. Chem. 269, 25710-25718[Abstract/Free Full Text]
  70. Ward, C., Omura, C., and Kopito, R. (1995) Cell 83, 121-128[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.